USFDA grants orphan drug designation to Zydus Cadila's Saroglitazar Mg
Posted by
www.biotecnika.org
Zydus Cadila, which is a part of Cadila Group, said orphan drug
designation provides eligibility for certain development incentives,
including tax credits for qualified clinical testing, prescription
drug user fee exemptions and seven-year marketing exclusivity upon
USFDA approval.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-grants-orphan-drug-designation-to-zydus-cadilas-saroglitazar-mg/articleshow/80494102.cms
Subscribe to:
Post Comments (Atom)
Post a Comment